Evidence map›Paper›PMID 41589955›Full record

ReviewBiomimetics (Basel, Switzerland)2026

Advancing Drug-Drug Interaction Prediction with Biomimetic Improvements: Leveraging the Latest Artificial Intelligence Techniques to Guide Researchers in the Field.

Ridwan Boya Marqas, Zsuzsa Simó, Abdulazeez Mousa, Fatih Özyurt, Laszlo Barna Iantovics

Abstract readReview
In one paragraph

Review in Biomimetics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ridwan Boya MarqasIT Department, College of Health and Medical Technology Shekhan, Duhok Polytechnic University, Duhok 42001, Iraq.ORCID 0000-0002-1071-3771
Zsuzsa SimóDepartment of Electrical Engineering and Information Technology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540142 Târgu Mureș, Romania.ORCID 0000-0002-8426-5772
Abdulazeez MousaDepartment of Computer Science, Nawroz University, Duhok 42001, Iraq.ORCID 0000-0003-1590-1875
Fatih ÖzyurtDepartment of Software Engineering, Engineering Faculty, Firat University, Elazig 23119, Turkey.ORCID 0000-0002-8154-6691
Laszlo Barna IantovicsDepartment of Electrical Engineering and Information Technology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540142 Târgu Mureș, Romania.ORCID 0000-0001-6254-9291

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-drug interactions (DDIs) can cause adverse reactions or reduce the efficiency of a drug. Using computers to predict DDIs is now critical in pharmacology, as this reduces risks, improves drug outcomes and lowers healthcare costs. Clinical trials are slow, expensive, and require a lot of effort. The use of artificial intelligence (AI), primarily in the form of machine learning (ML) and its subfield deep learning (DL), has made DDI prediction more accurate and efficient when handling large datasets from biological, chemical, and clinical domains. Many ML and DL approaches are bio-inspired, taking inspiration from natural systems, and are considered part of the broader class of biomimetic methods. This review provides a comprehensive overview of AI-based methods currently used for DDI prediction. These include classical ML algorithms, such as logistic regression (LR) and support vector machines (SVMs); advanced DL models, such as deep neural networks (DNNs) and long short-term memory networks (LSTMs); graph-based models, such as graph convolutional networks (GCNs) and graph attention networks (GATs); and ensemble techniques. The use of knowledge graphs and transformers to capture relations and meaningful data about drugs is also investigated. Additionally, emerging biomimetic approaches offer promising directions for the future in designing AI models that can emulate the complexity of pharmacological interactions. These upgrades include using genetic algorithms with LR and SVM, neuroevaluation (brain-inspired model optimization) to improve DNN and LSTM architectures, ant-colony-inspired path exploration with GCN and GAT, and immune-inspired attention mechanisms in transformer models. This manuscript reviews the typical types of data employed in DDI (pDDI) prediction studies and the evaluation methods employed, discussing the pros and cons of each. There are useful approaches outlined that reveal important points that require further research and suggest ways to improve the accuracy, usability, and understanding of DDI prediction models.

Indexed as

artificial intelligencebiomimetic computingbiomimetic machine learningcomputational pharmacologydeep learningdrug–drug interaction predictionensemble methodsgraph neural networksknowledge graphspharmacokinetics

Identifiers

PMID41589955
PMCPMC12839390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.